Steven Horner
About Steven Horner
Steven Horner is a Senior Research Associate at the Broad Institute of MIT and Harvard, specializing in protein engineering and cell pharmacology techniques. He has extensive experience in drug discovery and has worked in various research roles since 2009.
Work at Broad Institute
Steven Horner has been a Senior Research Associate at the Broad Institute of MIT and Harvard since 2020. In this role, he focuses on protein engineering and cell pharmacology techniques, particularly in modulating post-translational modifications (PTMs) and co-factor loading across various expression systems, including mammalian, insect, and E. coli. Prior to his current position, he served as Research Associate III from 2018 to 2020 and Research Associate II from 2017 to 2018 at the same institute, contributing to early-stage small molecule drug discovery campaigns.
Previous Experience
Before his tenure at the Broad Institute, Steven Horner worked at the University of Rochester Medical Center. He held the position of Laboratory Technician III from 2015 to 2016 and Laboratory Technician I from 2013 to 2015. His early research experience includes serving as an Undergraduate Researcher at the Rochester Institute of Technology from 2009 to 2011, where he began to develop his skills in laboratory techniques and research methodologies.
Education and Expertise
Steven Horner earned a Bachelor of Science degree in Molecular Bioscience and Biotechnology from the Rochester Institute of Technology, where he studied from 2008 to 2013. His educational background laid the foundation for his expertise in protein engineering and cell pharmacology, which he applies in his current research at the Broad Institute. His work involves developing x-ray crystallography systems to support structural projects and enhance structure-activity relationship (SAR) assessments in drug discovery.
Research Focus
In his research, Steven Horner specializes in developing techniques for protein engineering and cell pharmacology. He leads efforts in early-stage small molecule drug discovery, concentrating on construct design, protein purification, and biochemical and physical characterization. His work aims to advance understanding of post-translational modifications and improve the efficiency of drug discovery processes.